Amanda Kay

Amanda Kay is Senior Partner and Chief Business Development Officer at Flagship Pioneering. She joined Flagship in 2023 as an Operating Partner and President of Metaphore Biotechnologies. A biologist by training, Amanda brings broad experience from pharmaceutical and biotechnology companies in business development, strategy, operations, and financial planning, together with a passion for working with scientists to translate innovative drug platform technologies into products that address unmet patient need.

Prior to joining Flagship Pioneering, Amanda was Chief Business Officer and Head of Finance at Deep Genomics where she led strategy and business development, raising a successful Series C to develop an AI-driven drug discovery platform and emerging portfolio. As Senior Vice President of Corporate Development at Synlogic, Inc., a clinical-stage company, she led business development, corporate strategy, alliance management, and new product commercialization efforts for a new class of living medicines. She played a key role in defining the company’s strategy, leading to both the company’s public launch and financings.

Prior to joining Synlogic, Amanda served as Chief Operating Officer for Pfizer’s Inflammation and Immunology Research Unit, driving development of strategy and operations across portfolio, BD, finance, and HR functions. Ultimately, the unit delivered an industry-leading pipeline with eight programs advancing into Phase 2 studies. Previously, Amanda was a strategic lead on the marketing team for transplant and oncology products at Genzyme. She began her business career at L.E.K. Consulting, where she led more than fifty engagements, with clients ranging from start-ups to pharmaceutical companies.

Amanda received her B.A. in bacteriology from the University of Wisconsin, Madison, graduating both summa cum laude and Phi Beta Kappa. She received her Ph.D. in biology from Harvard University.